Federated Hermes
CRNX icon

Federated Hermes’s Crinetics Pharmaceuticals CRNX Stock Holding History

Federated Hermes’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$590K Buy
+16,248
New +$726K ﹤0.01% 1255
2024
Q3 		– Sell
-15,768
Closed -$706K – 2078
2024
Q2 		$706K Buy
15,768
+12,291
+353% +$568K ﹤0.01% 1217
2024
Q1 		$163K Buy
3,477
+3,459
+19,217% +$135K ﹤0.01% 1525
2023
Q4 		$640 Sell
18
-6
-25% -$184 ﹤0.01% 2001
2023
Q3 		$714 Buy
+24
New +$495 ﹤0.01% 2024
2022
Q2 		– Sell
-25,482
Closed -$559K – 2172
2022
Q1 		$559K Buy
25,482
+646
+3% +$13.1K ﹤0.01% 1421
2021
Q4 		$706K Buy
+24,836
New +$612K ﹤0.01% 1379
2020
Q3 		– Sell
-64
Closed -$1K – 2261
2020
Q2 		$1K Sell
64
-29
-31% -$494 ﹤0.01% 2134
2020
Q1 		$1K Buy
+93
New +$1.91K ﹤0.01% 2095

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Federated Hermes's CRNX Position: Q1 2026 in Review

Federated Hermes opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 16,248 shares worth $590K. The stake represents ﹤0.01% of the portfolio and ranks #1255 among its holdings. This is a return to the name: Federated Hermes previously reported a position in CRNX as recently as Q2 2024.

Federated Hermes first reported a position in CRNX in Q1 2020 and has held it in 9 quarters since. The position peaked at $706K in Q2 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Federated Hermes held 16,248 shares of Crinetics Pharmaceuticals worth $590K as of Q1 2026.
  • Crinetics Pharmaceuticals was a new Federated Hermes position in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1255 holding.
  • Federated Hermes first reported a position in Crinetics Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
  • Federated Hermes's Crinetics Pharmaceuticals position peaked at $706K in Q2 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.